Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET/MR in Hepatocellular Carcinoma
NCT05006326Unknown
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of gallium ga-68 gozetotide in hepatocellular carcinoma (HCC). Primary endpoints: Sensitivity of 68Ga-PSMA PET/MR at 1 year and Specificity of 68Ga-PSMA PET/MR at 1 year. Status: unknown.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05006326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006326.